Metastatic Malignant Solid Neoplasm Clinical Trials in Lexington, Kentucky

4 studies are recruiting for metastatic malignant solid neoplasm in Lexington, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

   This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) …

   Stage

   Phase 2

   Ages

   Any age

   Site

   CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington, Kentucky

   Locations

   482 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564377 on ClinicalTrials.gov

2. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

   This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Kentucky/Markey Cancer Center, Lexington, Kentucky

   Locations

   18 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05372614 on ClinicalTrials.gov

3. Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

   This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works in treating patients with solid tumor cancers that…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Kentucky/Markey Cancer Center, Lexington, Kentucky

   Locations

   27 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06311214 on ClinicalTrials.gov

4. Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

   This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Kentucky/Markey Cancer Center, Lexington, Kentucky

   Locations

   36 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05327010 on ClinicalTrials.gov